Browsing by Author "Paksoy Turkoz, Fatma"
Now showing items 1-2 of 2
-
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Tural, Deniz; Olmez, Omer Fatih; Sumbul, ahmet Taner; Ozhan, Nail; Cakar, Burcu; Paksoy Turkoz, Fatma; Kilickap, Saadettin (Springer, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Tatli , Ali Murat; Erdem, Dilek; Goker, Erdem; Celik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atci , Muhammed Mustafa; Bayram, Ertuğrul; Akın Telli, Tuğba; Bilgin, Burak; Bilici, Ahmet; Akangunduz , Baran; Balli, Sevinç; Demirkazik, Ahmet; Selçukbiricik, Fatih; Menekse, Serkan; Cavdar, Eyyüp; Ozturk, Akın; Türkmen Bekmez, Esma; Turhal, Serdal; Kilickap, Sadettin; Yildirim, Hasan Çağrı; Oyan, Başak; Aksoy, Asude; Paksoy Turkoz, Fatma; Kut, Engin; Katgi, Nuran; Sakalar, Teoman; Akyol, Murat; Ellez, Halil İbrahim; Topcu, Atakan; Erdoğan, Atike Pınar; Pilanci, Kezban Nur; Hedem, Engin; Arak, Hacı; Akdeniz, Nadiye; Alan, Özkan; Yapar, Burcu; Nart, Deniz; Yumuk, Perran Fulden (Springer, 2022)Objectives To compare the survival of frst- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...
